Verona.jpg
Verona Pharma to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
February 18, 2021 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona.jpg
CORRECTING and REPLACING -- Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD
February 02, 2021 06:17 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Feb. 02, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Verona Pharma plc (Nasdaq: VRNA), please note that all instances of the unit...
Verona.jpg
Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD
February 02, 2021 02:00 ET | Verona Pharma plc
Primary and secondary lung function endpoints met Results support twice-daily dosing LONDON and RALEIGH, N.C., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”),...
Verona.jpg
Verona Pharma Completes Enrollment in Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19
January 14, 2021 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona.jpg
Verona Pharma to Present at H.C. Wainwright Virtual BioConnect Conference
January 05, 2021 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona.jpg
Verona Pharma Secures up to $30 Million Debt Financing from Silicon Valley Bank
November 23, 2020 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
Verona.jpg
Verona Pharma Announces November 2020 Virtual Investor Conference Participation
November 09, 2020 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona.jpg
Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2020
October 29, 2020 03:00 ET | Verona Pharma plc
Initiated ENHANCE Phase 3 clinical trials in COPD Completed $200 million private placement Commenced a pilot clinical study in U.S. patients hospitalized with COVID-19 ...
Verona.jpg
Verona Pharma plc : Update on AIM Delisting
October 28, 2020 07:01 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), provides a further update with regards to its intended...
Verona.jpg
Verona Pharma to Announce Interim Results for the Three and Nine Months Ended September 30, 2020 and Provide Corporate Update
October 22, 2020 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases,...